EP0993318A1 - Vorrichtung zur optimierten elektrotransfer der nukleinsäuren vektoren an gewebe in vivo - Google Patents
Vorrichtung zur optimierten elektrotransfer der nukleinsäuren vektoren an gewebe in vivoInfo
- Publication number
- EP0993318A1 EP0993318A1 EP98938676A EP98938676A EP0993318A1 EP 0993318 A1 EP0993318 A1 EP 0993318A1 EP 98938676 A EP98938676 A EP 98938676A EP 98938676 A EP98938676 A EP 98938676A EP 0993318 A1 EP0993318 A1 EP 0993318A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pulses
- electrode
- tissue
- volts
- electrotransfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 97
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 95
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 95
- 238000001727 in vivo Methods 0.000 title claims abstract description 25
- 239000013598 vector Substances 0.000 title abstract description 17
- 230000005684 electric field Effects 0.000 claims abstract description 143
- 210000001519 tissue Anatomy 0.000 claims abstract description 102
- 238000012546 transfer Methods 0.000 claims abstract description 75
- 210000003205 muscle Anatomy 0.000 claims description 124
- 230000001976 improved effect Effects 0.000 claims description 14
- 229910001220 stainless steel Inorganic materials 0.000 claims description 7
- 239000010935 stainless steel Substances 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 5
- 238000007910 systemic administration Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 54
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 210000000663 muscle cell Anatomy 0.000 abstract description 8
- 238000013508 migration Methods 0.000 abstract description 3
- 230000005012 migration Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 149
- 239000013612 plasmid Substances 0.000 description 117
- 230000014509 gene expression Effects 0.000 description 102
- 108020004414 DNA Proteins 0.000 description 93
- 241000699670 Mus sp. Species 0.000 description 71
- 239000007924 injection Substances 0.000 description 64
- 238000002347 injection Methods 0.000 description 64
- 206010028980 Neoplasm Diseases 0.000 description 62
- 238000001890 transfection Methods 0.000 description 60
- 238000002474 experimental method Methods 0.000 description 47
- 230000000694 effects Effects 0.000 description 42
- 108060001084 Luciferase Proteins 0.000 description 38
- 239000005089 Luciferase Substances 0.000 description 38
- 238000011282 treatment Methods 0.000 description 35
- 108700019146 Transgenes Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 27
- 230000001225 therapeutic effect Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 230000002132 lysosomal effect Effects 0.000 description 24
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 22
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 21
- 108090000742 Neurotrophin 3 Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 102000004230 Neurotrophin 3 Human genes 0.000 description 20
- 238000001415 gene therapy Methods 0.000 description 19
- 229940032018 neurotrophin 3 Drugs 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 241001529936 Murinae Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000004520 electroporation Methods 0.000 description 11
- 201000005296 lung carcinoma Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000008488 polyadenylation Effects 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- -1 polyethylenimine Chemical class 0.000 description 8
- 102100026189 Beta-galactosidase Human genes 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000002870 angiogenesis inducing agent Substances 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000003387 muscular Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229960003299 ketamine Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000003365 myofibril Anatomy 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 5
- 229960001600 xylazine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102400000068 Angiostatin Human genes 0.000 description 4
- 108010079709 Angiostatins Proteins 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 201000010897 colon adenocarcinoma Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 229960000027 human factor ix Drugs 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 210000003699 striated muscle Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000001228 trophic effect Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 229960005356 urokinase Drugs 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 3
- 102400001047 Endostatin Human genes 0.000 description 3
- 108010079505 Endostatins Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 3
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 229960004222 factor ix Drugs 0.000 description 3
- 102000058223 human VEGFA Human genes 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000508 neurotrophic effect Effects 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 102100028496 Galactocerebrosidase Human genes 0.000 description 2
- 108010042681 Galactosylceramidase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010029389 Simplexvirus glycoprotein B Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GIAKYHPCRXMSHO-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;2-oxopentanedioic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O GIAKYHPCRXMSHO-JEDNCBNOSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 description 1
- 102000004672 Acetyl-CoA C-acyltransferase Human genes 0.000 description 1
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 102100022146 Arylsulfatase A Human genes 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 108010023546 Aspartylglucosylaminase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100031006 Beta-Ala-His dipeptidase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101710085496 C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 102000007132 Carboxyl and Carbamoyl Transferases Human genes 0.000 description 1
- 108010072957 Carboxyl and Carbamoyl Transferases Proteins 0.000 description 1
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 1
- 108010004942 Chylomicron Remnants Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 102000030789 Histidine Ammonia-Lyase Human genes 0.000 description 1
- 108700006308 Histidine ammonia-lyases Proteins 0.000 description 1
- 101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101001060265 Homo sapiens Fibroblast growth factor 6 Proteins 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101001047912 Homo sapiens Hydroxymethylglutaryl-CoA lyase, mitochondrial Proteins 0.000 description 1
- 101000609261 Homo sapiens Plasminogen activator inhibitor 2 Proteins 0.000 description 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 description 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 description 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100024004 Hydroxymethylglutaryl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 101150108210 IX gene Proteins 0.000 description 1
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010022203 Leucine transaminase Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000859568 Methanobrevibacter smithii (strain ATCC 35061 / DSM 861 / OCM 144 / PS) Carbamoyl-phosphate synthase Proteins 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 108010085747 Methylmalonyl-CoA Decarboxylase Proteins 0.000 description 1
- 102000019010 Methylmalonyl-CoA Mutase Human genes 0.000 description 1
- 108010051862 Methylmalonyl-CoA mutase Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102100021003 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase Human genes 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 101710202061 N-acetyltransferase Proteins 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000622060 Photinus pyralis Luciferin 4-monooxygenase Proteins 0.000 description 1
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical group C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 108010079870 Sarcosine Dehydrogenase Proteins 0.000 description 1
- 102000013000 Sarcosine dehydrogenase Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102100028748 Transportin-1 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 1
- 108010042606 Tyrosine transaminase Proteins 0.000 description 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100037814 Vigilin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 102100038138 WD repeat-containing protein 26 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 108010070626 acid beta-galactosidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 108010014977 glycine cleavage system Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 108010092427 high density lipoprotein binding protein Proteins 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108010053156 lipid transfer protein Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
Definitions
- This invention is directed to remarkable enhancement of in vivo transfer into cells, particularly muscle cells, of nucleic acid vectors using weak electric fields, to increase the efficiency of such transfers.
- the invention specifically relates to methods, devices, and compositions that effect such nucleic acid vector transfer for gene therapy.
- the devices of the invention are designed to provide an optimum voltage gradient to enhance migration of nucleic acid vectors into cells, without damaging the cells or tissue.
- Such devices are characterized by unique arrangements of electrodes, and by unique power limits defined by maximum voltage settings.
- pretreatment of the tissue to be injected with solutions intended to enhance DNA diffusion and/or stability (Davis et al., 1993, Hum. Gene Ther. 4, 151-159) or to favor the entry of nucleic acids, e.g., the induction of cell multiplication or regeneration phenomena.
- the treatments have concerned, in particular, the use of local anesthetics or cardiotoxin, vasoconstrictors, endotoxin or other molecules (Manthorpe et al., 1993, Human Gene Ther. 4, 419-431; Danko et al., 1994, Gene Ther. 1, 114-121; Vitadello et al., 1994, Hum. Gene Ther. 5, 11-18).
- These pretreatment protocols are difficult to manage.
- Bupivacaine in particular, must be used at very close to lethal doses in order to be effective.
- the pre- injection of hyperosmotic sucrose, intended to enhance diffusion, does not increase the level of transfection in the muscle (Davis et al., 1993).
- Electroporation and Iontophoresis for Gene Delivery Electroporation is commonly used in vitro to promote DNA transfection in culture cells. This phenomenon depends on achieving a threshold electric field strength. Electropermeabilization was observed at electric fields of relative high intensity, in the order of 800 to 1,200 volts/cm for animal cells. This technique was also proposed in vivo in order to enhance the efficacy of antitumoral agents, like bleomycin, in solid tumors in man (US patent No. 5,468,228, L.M. Mir). With pulses of very short duration (100 microseconds), these electric conditions (800 to 1,200 volts/cm) are very well adapted to the intracellular transfer of small molecules.
- Electrodes are positioned externally with respect to the patient. See, for example, US Patent Nos. 5,318,514 to Hofmann; 5,439,440 to Hofmann; 5,462,520 to Hofmann; 5,464,386 to Hofmann; 5,688,233 to Hofmann et al.; and 5,019,034 to Weaver et al.; the disclosures of which are inco ⁇ orated herein by reference.
- an external electrode device the electrodes are in contact with a surface tissue region of a patient. The device can be used non- invasively by applying the electrodes to the skin of the patient or invasively by applying the electrodes to the surface of an organ that has been exposed surgically.
- the Hofmann '514 patent discloses a device that is used to implant macromolecules such as genes, DNA or pharmaceuticals into a preselected surface tissue region of a patient.
- the device has a head assembly which includes, in a first embodiment, a se ⁇ entine conductor positioned on an open-pore elastomer, both of which are carried on a generally planar support member. Adjacent parallel segments of the serpentine conductor serve as electrodes.
- the head assembly is placed in contact with the preselected surface tissue region of the patient, placing the conductor in contact with the skin.
- a liquid medium carrying the macromolecules is transferred to the skin of the patient by delivery to the elastomer of the liquid which is absorbed or soaked up by the elastomer.
- a switch is then engaged to deliver a high voltage pulse from a signal generator to the electrodes, causing an electric field to be generated across the electrodes.
- the depth of the electric field into the skin is proportional to the gap between the electrodes. The electric field injects the liquid into the tissue region.
- the head assembly includes a plurality of fine needles extending generally perpendicular to the planar support member.
- the needles are arranged in rows and are connected alternatively to the output of the signal generator so that each needle is adjacent another needle of opposite polarity.
- the needles penetrate the outer most layers of skin cells and facilitate the administration of the electric pulses into the target area.
- the Hofmann '440 patent discloses an apparatus which includes adjustably spaced electrodes for generating an electric field.
- the electrodes are mounted on a moveable linkage so that the electrodes can be manipulated by the user to move toward and away from one another like the jaws of a clamp.
- the electrode jaws are opened and a selected tissue to be treated is gripped between the electrode jaws.
- a signal generator connected to the electrodes is operated by a suitable switching device to generate the electric fields in the tissue between the electrodes.
- Internal Electrodes A second type of electrotransfer system utilizes implantable or insertable electrodes which are placed inside the patient to deliver an electric field to the area adjacent to the implanted/inserted electrode. See, for example, US Patent Nos.
- the Crandell '120 patent discloses a catheter that is inserted into a selected blood vessel of a patient.
- the catheter includes a plurality of axially extending, circumferentially spaced electrodes that are placed in contact with the inner wall of the blood vessel.
- a liquid medium containing the macromolecules is then infused into the blood vessel adjacent the electrodes and the electrodes are energized to apply the predetermined electrical signal for electrotransfer.
- the spaced electrodes can be se ⁇ entine or parallel strips which are energized to create the desired electric field.
- the Hofmann '724 patent is another example of a catheter-based electrotransfer device having spaced apart electrodes which are positioned on the outside of a catheter that is inserted into a blood vessel to contact the wall of the vessel to be treated.
- the Hofmann '662 patent discloses a pair of spaced apart electrodes mounted within a cylindrical dielectric carrier.
- the electrodes are positioned around the center of the blood vessel a predetermined uniform distance apart from each other and near the center of the vessel so that blood flowing in the vessel passes between the electrodes.
- the cylindrical dielectric carrier is implanted surgically within a surrounding blood vessel.
- a predetermined electrical signal is applied to the electrodes to create electric fields in the blood flowing between the electrodes.
- the Hofmann '525 patent discloses a dual-needle syringe in which the needles serve as the electrodes for carrying out the electrotransfer. Once the needles have been inserted into the target area, an electrical signal is applied to the electrodes to direct the electric field to the target area.
- the Hofmann '359 patent discloses also needle-based electrodes used for electrotransfer.
- a third type of electrotransfer device combines features of the above-mentioned systems. These devices utilize at least one internally placed electrode and at least one externally placed electrode to deliver the electric field to the desired tissue area. See, for example, US Patent No. 5,286,254 to Shapland et al.; 5,499,971 to Shapland et al.; 5,498,238 to Shapland et al.; 5,282,785 to Shapland et al.; and 5,628,730 to Shapland et al.; the disclosures of which are incorporated herein by reference.
- Typical of these devices is the one described in the Shapland '785 patent which discloses a catheter having a drug chamber with a drug delivery wall (for example, a wall made of permeable or semipermeable material which can pass drugs or other macromolecules therethrough) and an electrode located inside of the catheter in an opposed relation to the drug delivery wall.
- a second electrode is located at a remote site on a patient's skin.
- a liquid containing desired macromolecules is delivered to the drug chamber to be placed in the electric field generated between the two electrodes when they are provided with current. In this manner, the macromolecules are delivered to the target area.
- this invention concerns a process and device for nucleic acid transfer into tissues in vivo, e.g. , one or more striated muscles or tumors, in which the tissue cells are brought in contact with the nucleic acid to be transferred by direct administration into the tissue or by topical or systemic administration, and in which transfer is ensured by application to the tissues of one or more electric pulses of intensity ranging between 1 and 400 volts/cm for muscle, and 1 and 600 volts/cm for tissues such as tumors.
- the present invention provides a system, such as an improved apparatus, for in vivo nucleic acid transfer into cells of multicellular eukaryotic organisms, in which the tissue cells are brought in contact with the nucleic acid to be transferred by direct administration into the tissue or by topical or systemic administration, and in which transfer is ensured by application to the tissue of one or more electric pulses delivered by an apparatus of the invention set to provide the specified intensity.
- the electric field strength can range between 1 and 600 volts/cm for delivery of a nucleic acid to tumor cells, and between 1 and 400 volts/cm for delivery of a nucleic acid to muscle cells.
- the system (or apparatus) of the invention comprises an electrical pulse generator (or means for generating an electrical pulse), wherein the electrical pulse generator produces electric pulses with pulse times of greater than 1 millisecond and of intensity ranging between 1 and 400 or 600 volts/cm at a frequency of between 0.1 and 1000 Hz; and electrodes connected to the electrical pulse generator for generating an electric field in a tissue in vivo in contact with the electrodes.
- the electrical pulse generator produces pulse of intensity ranging between 30 and 300 volts/cm (for transfer into muscle) and between 400 and 600 V/cm for transfer into tumor cells and other small cells.
- the electrical pulse generator produces pulse times of greater than 10 milliseconds.
- the electrical pulse generator produces between 2 and 1000 pulses.
- the system or improved apparatus electrical pulse generator can produce pulses irregularly in relation to one another, whereby a function describing the intensity of the field dependent on time of an pulse is variable, with the proviso that at no time does the system or apparatus supply an electric field greater (or less) than the parameters set forth above.
- the integral of the function describing variation of the electric field with time can exceed 1 kV » msec/cm; and in a further embodiment exceeds or is equal to 5 kV* msec/cm.
- the electrical pulse generator (pulse generating means) can produce pulses selected from the group consisting of square-wave pulses, exponential decay waves, oscillating unipolar waves of limited duration, and oscillating bipolar waves of limited duration.
- the electrical pulse generator produces square- wave pulses.
- the electrode can be an external electrode for placement on a tissue to be treated, e.g. , for transferring nucleic acids into cells of a surface tissue of a subject.
- the electrode can be an internal electrode or tissue penetrating electrode, which is implantable in a tissue to be treated.
- Such an internal electrode can be a needle, and may be configured as an injector system making possible the simultaneous administration of nucleic acids and of the electric field.
- the invention provides both an external electrode and an internal electrode.
- An external electrode of the invention can be dimensionsed to contact an external portion of a subjects body in close proximity to a large muscle.
- such an electrode is a flat plate electrode; in another embodiment, it is a semi-cylindrical plate electrode.
- the an electrode is an intra-arterial or intravenous electrode, for example a flexible catheter apparatus modified according to the invention.
- the preferred material for an electrode of the invention is stainless steel.
- the improved apparatus of the invention can be produced by modifying prior art devices, and particularly the means for generating an electric field of such devices, to generate an electric field of the invention.
- the means for generating an electric pulse can be adapted to produce pulses ranging between 1 and 400 or 600 volts/cm by modifying the voltage gate not to exceed a voltage corresponding to 400 or 600 volts/cm.
- the voltage can be set at a constant voltage and the electrodes can be set at a constant spacing distance.
- the means for generating an electric pulse can be adapted to produce pulses ranging between 1 and 400 or 600 volts/cm by labeling the device not to exceed a voltage corresponding to 400 or 600 volts/cm.
- an object of the invention is to provide a system, or improve existing devices, to supply an electric field having a voltage gradient, pulse width, and number of pulses that have been found to be optimum for transfer of nucleic acids without damaging tissue.
- Yet another advantage of the invention is to provide for efficient, reproducible delivery of nucleic acids to muscle cells.
- FIGURE 1 Effects of electric pulses of high field intensity on the transfection of plasmid DNA pXL2774 in the cranial tibial muscle in the mouse; mean values ⁇ SEM.
- FIGURE 2 Effects of electric pulses of intermediate field intensity on the transfection of plasmid DNA pXL2774 in the cranial tibial muscle in the mouse; mean values ⁇ SEM.
- FIGURE 3 Effects of electric pulses of weak field intensity and of different duration on the transfection of plasmid DNA pXL2774 in the cranial tibial muscle in the mouse; mean values ⁇ SEM.
- FIGURE 4 Effects of electric pulses of weak field intensity and of different duration on the transfection of plasmid DNA pXL2774 in the cranial tibial muscle in the mouse; mean values ⁇ SEM.
- FIGURE 5 Effectiveness of electrotransfer of plasmid DNA pXL2774 in the cranial tibial muscle of the mouse at low electric field intensities; mean values ⁇ SEM.
- FIGURE 6 Kinetics of expression of luciferase in mouse tibial cranial muscle. Administration of plasmid pXL2774 with (B)and without (X) electrotransfer; average values + SEM.
- FIGURE 7 Level of expression as a function of the dose of DNA administered with (•) and without (D)electrotransfer.
- FIGURE 8 Effect of different types of electrodes on electrotransfer efficiency.
- FIGURE 9 Kinetics of serum concentration of secreted alkaline phosphate. Administration of plasmid ⁇ XL3010 with ( ⁇ ) et without ( ⁇ ) electrotransfer; average values + SEM.
- FIGURE 10 Kinetics of expression of aFGF in muscle with (open histogram bars) or without (solid histogram bars) electrotransfer.
- FIGURE 11 Map of plas ids pXL3179 and pXL3212.
- FIGURE 12 Map of plasmids pXL3388 and pXL3031.
- FIGURE 13 Map of plasmids pXL3004 and pXL3010.
- FIGURE 14 Map of plasmids pXL3149 and pXL3096.
- FIGURE 15 Map of plasmids pXL3353 and pXL3354.
- FIGURE 16 Map of plasmid pXL3348.
- the present invention provides greatly enhanced in vivo nucleic acid transfer into tissues by subjecting the tissue to electric pulses of low intensity.
- electric fields of less than 600 volts/cm have been found to enhance nucleic acid transfer into tumors, and less than 400 volts/cm, and preferably, 100 to 200 volts/cm for electrodes placed about 0.5 to 1 cm apart in muscle. These fields are applied for relatively long duration.
- the applicants discovered that the wide variability of transgene expression observed in the prior art of DNA transfer into the muscle was notably reduced by the process according to the invention.
- expression persists for a long period of time, e.g., greater than 60 days. In a specific example, high level expression was detected 63 days.
- electrotransfer transfer of nucleic acids into cells in vivo under these conditions
- electrotransfection an appropriate alternative term used herein is “electrotransfection”. Both of these terms distinguish the optimized conditions for nucleic acid transfer from “electroporation” (using electric fields greater than 800 V/cm) and iontophoresis (using very low strength electric fields).
- this invention concerns processes, systems and devices (or apparatus), and compositions for in vivo nucleic acid transfer into tissues, particularly striated muscle, in which the tissue cells are brought in contact with the nucleic acid to be transferred by direct administration into the tissue or by topical or systemic administration, and in which transfer is ensured by application to said tissues of one or more electric pulses of intensity ranging between 1 and 600 volts/cm (e.g. for tumor cells) or between 1 and 400 volts/cm for muscle cells.
- the present invention particularly concerns systems ⁇ i.e., devices or apparatus) for electrotransfer.
- the process of the invention is applied to tissues whose cells have particular geometries, like, for example, cells of large size and/or of elongated shape and/or naturally responding to electric potentials and/or having a specific mo ⁇ hology.
- the intensity of the field preferably ranges between 4 and 400 volts/cm for muscle, and up to 600 volts/cm for tumors, and the total duration of application exceeds 1 millisecond
- the total duration is 8 msec or longer.
- the pulse duration is 20 msec, and durations greater than 40 msec were found to be effective.
- the number of pulses used is, for example, from 1 to 1,000 pulses, preferably 2 to 100 and more preferably 4 to 20, and the pulse frequency ranges between 0.1 and 1,000 hertz (Hz); more precisely between 0.2 and 100 Hz. In specific embodiments, frequencies of 2, 3, and 4 Hz were found to be effective.
- the pulses can also be delivered irregularly and the function describing the intensity of the field dependent on time can be variable. The integral of the function describing the variation of the electric field with time is greater than 1 kV»msec/cm.
- that integral is higher than or equal to 5 kV » msec/cm.
- this integrated function must be achieved at the sub-electrophoretic voltages described supra.
- the device of the invention can supply a combination of at least one higher voltage pulse (greater than 400 V/cm, and preferably between 500 and 800 V/cm) for short duration (less than 1 msec), followed by one or more longer pulses (greater than 1 msec) at much lower electric field strength (less than 200 V/cm).
- the field intensity of the pulses ranges between 30 and 300 volts/cm.
- the electric pulses are chosen among square-wave pulses, the electric fields generating exponential decay waves, oscillating unipolar waves of limited duration, oscillating bipolar waves of limited duration or other wave-forms.
- the electric pulses are square wave pulses.
- the administration of electric pulses can be carried out by any method known in the art, e.g.:
- Nucleic acids can be administered by any appropriate means, but are preferably injected in vivo directly into the tissues or administered by another route, local or systemic, which makes them available on the site of application of the electric field.
- the nucleic acids can be administered with agents permitting or facilitating transfer, as previously mentioned.
- Those nucleic acids can, notably, be free in solution or linked to synthetic agents or carried by viral vectors.
- the synthetic agents can be lipids or polymers known to the expert, or even targeting elements making possible fixation on the membrane of the target tissues. Among those elements, vectors carrying sugars, peptides, antibodies, receptors, and ligands, can be mentioned.
- nucleic acids can precede, be simultaneous or even follow the application of electric fields, provided of course that the electric field continues to be applied after the nucleic acid is administered.
- This invention also concerns a nucleic acid and an electric field of intensity ranging between 1 and 600 volts/cm (preferably 400 volts/cm), as a combination product for their simultaneous, separate or time-staggered in vivo administration into mammal cells and, in particular, into human cells.
- the intensity of the field preferably ranges between 4 and 400 volts/cm and, even more preferably, the field intensity ranges between 30 and 300 volts/cm for transfer into muscle.
- a preferred electric field intensity is 400-600 V/cm; preferably about 500 (i.e., 500 ⁇ 10%, preferably 5%) V/cm .
- such a combination defines a nucleic acid structure, in which the nucleic acid adopts a specific orientation relative to the electric field, as well as specific secondary and tertiary structure in the presence of the electric field.
- the DNA will be associated with the extracellular components found in the target tissue, which is in distinction to DNA undergoing low field electrophoresis in an agarose gel or other laboratory conditions.
- any electrotransfer system consist of an electric pulse generator that is designed or modified to provide pulses of no more than 600 V/cm, and electrodes.
- a system or apparatus of the invention for delivery of a nucleic acid specifically to muscle provides pulses of no more than 400 volts/cm.
- the actual voltage will depend on the distance between the electrodes. As is well known in the art, this distance affects the specific resistance (resistivity) through the target tissue. Accordingly, the actual voltage applied will depend on the resistance so that current, and thus the total power, is kept within acceptable levels.
- accepted levels as used herein means that the total power does not result in irreversible tissue damage, particularly tissue burning.
- the apparatus of the invention either controls for acceptable current by fixing voltage and electrode distance, or includes a feedback means to prevent applying too high a voltage for the distance between the electrodes, and thus too much current.
- a system of the invention may include an oscilloscope or other metering device to monitor voltage, current, or both.
- the system of the invention is prepared using commercially available equipment. Preferably, such equipment is modified to provide the specific electrotransfer conditions defined herein as optimal. In another embodiment, a new apparatus is designed and built to achieve the objectives of the invention.
- Design specifications of the modified or built pulse generator include, but are by no means limited to, incorporation of a mechanical or electrical controller to maintain the desired voltage gradient, i.e., less than 600 or 400 V/cm, and preferably less than 200 V/cm for administration to muscle.
- a mechanical control could include, for example, a stop on the voltage selection dial that prevents selection of a voltage that would yield too high an electric field.
- the device can be built or modified to that such voltages cannot be selected.
- the device can include a breaker or fuse that will trip when the voltage (and thus current) exceeds the parameters of the invention.
- microprocessor controls can prevent or override selection of too great a voltage.
- a pulse generator is modified simply by applying a label directing use of a particular voltage range that provides the electric field strength of the invention. All of these modifications are routine in the art, and employ standard electrical and mechanical technologies.
- the actual voltage delivered by a system of the invention to achieve the electric field strength defined herein as optimal will depend, in part, on the electrode spacing. If the electrodes are spaced apart in a fixed manner, then the voltage (for a defined tissue, e.g., muscle, liver, heart, or a tumor) may be a pre-defined constant. However, if it is desirable to provided for varying the spacing of the electrodes, then the voltage may have to be adjusted to maintain a constant voltage gradient. This can be determined by measuring the distance between the electrodes, by including measuring means on the electrodes that provides a value for their spacing after adjustment, or by automated measuring means that feedback to the pulse generator to automatically provide the correct voltage (see US Patent 5,439,440 to Hofmann).
- Pulse generators are electrical devices that produce a current of defined voltage, duration, pulse width, duty cycle (the total time of the pulsing and resting), and pulse frequency. Such devices are well known in the art, and include commercially available pulse generators such as the ELECTRO CELL MANIPULATOR Model ECM 600, T800L and T820 voltage generators available from the BTX Instruments Division of Genetronics, Inc. of San Diego, California, e.g. , as described in US Patent No. 5,704,908, which is inco ⁇ orated herein by reference in its entirety.
- the pulse generator can be an Electropulsator PS 15, available from Jouan, France, as disclosed in the Examples, infra.
- a voltage generator that can produce one or more of the wave forms described in US Patent No. 5,634,899, which is incorporated herein by reference in its entirety, can be used.
- the voltage can be designed to generate pulses of variable shape, intensity, and duration. For example, a pulse of 200 V/cm or 400 V/cm, 5-20 msec, could be followed by a lower intensity, longer pulse.
- the device could further supply iontophoretic electric fields in combination with electric fields of the invention.
- a pulse generator of the invention will have the following specifications:
- pulse time greater than 1 millisecond (msec), with variable duty times; preferably the pulse time is greater than 5 msec; more preferably greater than 10 msec; and more preferably still greater than 20 msec.
- the pulse generator of the invention produces at least two, and preferably four, six or eight pulses. It can produce, for example, between 8 and 1,000 pulses.
- the pulse generator should permit an override or cut-off if the patient begins to experience an adverse event or the electric field strength is out of control. Such an override could be manual or automatic, or both.
- pulses can be generated by an external signal, such as another device, a computer, etc.
- the pulse generator will optimally interface with the subject's electrocardiogram so that pulses are synchronized with the heart beat.
- Such a system preferably includes active pacing of the subject's cardiac rhythm, e.g. with a pacemaker (see US Patent No. 5,634,899 to Shapland).
- Electrodes The electrodes of the invention provide the electric field in the tissue. One electrode, the cathode, is negatively charged; the anode is positively charged.
- an electrode for use according to the invention must conduct electricity efficiently, and preferably is inert, non-reactive and non-toxic under the conditions used.
- an electrode for internal use should not react with biological materials to any appreciable degree, e.g., to avoid releasing metal ions from the electrode that could be harmful or poisonous, or to avoid oxidation that reduces electrode efficiency.
- a preferred material for electrodes of the invention is stainless steel, which is fairly non-reactive, reasonably efficient for conducting electricity, and inexpensive enough to be manufactured at a reasonable cost. More ideal electrodes, particularly for internal use, are gold or platinum. However, such noble metal electrodes are very expensive. The cost of these materials can be reduced by plating them over other conductors. Other conductive metals include copper, silver or silver chloride, tin, nickel, lithium, aluminum, and iron, and amalgams thereof. However, certain materials, such as aluminum, should not be used internally. Electrodes can also be formed from zirconium, iridium, titanium, and certain forms of carbon.
- Some electrodes such as silver and copper, have antibacterial activity, which could be desirable for internal administration to suppress infection.
- the electrodes can be formed in any configuration appropriate for the target tissue, including, without limitation, straight wires, coiled wires (straight and coiled wire electrodes are ideal for catheter applications) , conductive surfaces ⁇ e.g., of catheters or balloon catheters; see US Patent No. 5,704,908, inco ⁇ orated herein by reference in its entirety), metal strips, needles (or probes), arrays of needles, surface electrodes, or combinations thereof.
- Contemplated electrode combinations include (1) a catheter electrode and a needle electrode; (2) a catheter electrode and a surface electrode; and (3) a needle electrode and a surface electrode.
- a needle electrode can be used with a syringe to deliver DNA.
- Such a needle electrode can have holes through the length of its shaft to permit delivery of the nucleic acid solution throughout its length.
- two surface electrodes can be used.
- Surface electrodes are preferably used in combination with an electrolytic composition to ensure good contact and conductance, e.g. , through the skin, as described above.
- the external electrode can have multiple "heads" placed around the internal one. Indeed, in general for any of the configurations set forth above, one of the electrodes can have multiple "heads.”
- the invention further contemplates arrays of electrodes; needles with holes along the shaft; needles with defined and calibrated conductive length (to provide constant and reproducible conductive area into a tissue, whatever the depth of the penetration of the needle into a tissue), with the upper and lower parts being electrically isolated; needles with isolated points, to prevent point to point electrical arcs into a tissue; and any kind of pouch / reservoir containing the product around one needle.
- needle electrodes can comprise isolated margins.
- the electrodes are arranged so that the target tissue is directly between them. That way, the nucleic acids are subject to the maximum field strength. However, since the electric field flux is all around the electrode, it is possible to use the field generated peripherally between the electrodes as well as the field generated directly between the electrodes.
- an apparatus in which electrodes are positioned externally with respect to the patient is modified in accordance with the present invention, i.e., to supply an electric field under the defined conditions, to provide an improved apparatus of the invention.
- the improved apparatus can be used non-invasively by applying the electrodes to the skin of the patient or invasively by applying the electrodes to the surface of an organ that has been exposed surgically.
- an electrotransfer system that utilizes implantable or insertable electrodes placed inside the patient to deliver an electric field to the area adjacent to the implanted/inserted electrode, particularly a catheter electrode (see, for example, US Patent Nos. 5,304,120 to Crandell et al.; 5,507,724 to Hofmann et al.; 5,501,662 to Hofmann; 5,702,359 to Hofmann et al.; and 5,273,525 to Hofmann) can be modified in accordance with the present invention to yield an improved apparatus of the invention.
- an electrotransfer device that combines features of the above-mentioned systems, e.g., that utilize at least one internally placed electrode and at least one externally placed electrode to deliver the electric field to the desired tissue area (see, for example, US Patent No. 5,286,254 to Shapland et al.; 5,499,971 to Shapland et al.; 5,498,238 to Shapland et al.; 5,282,785 to Shapland et al.; and 5,628,730 to Shapland et al)can be modified in accordance with the present invention to provide an improved apparatus of the invention.
- the process according to this invention is useful for gene therapy, that is, therapy in which the expression of a transferred gene, but also the modulation or blocking of a gene, makes it possible to ensure treatment of a particular pathology.
- tissue cells are preferably treated with a view to gene therapy making possible:
- the protection and/or regeneration of vascularization or innervation of the tissue such as muscles, organs or bone, by trophic, neurotrophic, angiogenic factors, or by anti- inflammatory factors produced by the transgene; the transformation of muscle into an organ secreting products leading to a therapeutic effect, such as the product of the gene itself (for example, thrombosis and hemostasis regulation factors, trophic factors, growth factors, hormones like insulin, erythropoietin, and leptin, etc.) or such as an active metabolite synthesized in the muscle by addition of the therapeutic gene e.g., to correct a genetic disease by secretion of a therapeutic product;
- a therapeutic effect such as the product of the gene itself (for example, thrombosis and hemostasis regulation factors, trophic factors, growth factors, hormones like insulin, erythropoietin, and leptin, etc.) or such as an active metabolite synthesized in the muscle by addition of the
- anti-tumor genes such as tumor suppressors (retinoblastoma protein, p53, p71), suicide genes ⁇ e.g., HSV-thymidine kinase), anti-angiogenesis genes ⁇ e.g., angiostatin, endostatin, amino terminal fragement of urokinase), cell cycle blockers, apoptosis genes (such as BAX) intracellular single chain antibodies, and immunostimulatory genes.
- tumor suppressors retinoblastoma protein, p53, p71
- suicide genes ⁇ e.g., HSV-thymidine kinase
- anti-angiogenesis genes e.g., angiostatin, endostatin, amino terminal fragement of urokinase
- cell cycle blockers e.g., apoptosis genes (such as BAX) intracellular single chain antibodies, and immunostimulatory genes.
- apoptosis genes such as BAX
- this invention could be applied to the cardiac muscle for the treatment of heart diseases, e.g., using cardiac pacing to ensure safe electrotransfer (see US Patent No. 5,634,899). It could also be applied to the treatment of restenosis by the expression of genes inhibiting smooth muscle cell proliferation like the GAX protein.
- the combination of fields of low intensity and long duration of administration enhances the transfection of nucleic acids, without causing notable tissue deterioration. These results enhance the efficiency of DNA transfers in gene therapy employing nucleic acids. Consequently, the advantages associated with the invention are the production of an agent at physiologic and/or therapeutic doses either in the tissues or in proximity thereto, or secreted systemically in the blood stream or lymph circulation. Furthermore, the invention makes possible, for the first time, fine modulation and control of the effective quantity of transgene expressed by the possibility of modulating the volume of the tissue to be transfected, for example, with multiple administration sites, or even the possibility of modulating the number, shape, surface and arrangement of the electrodes.
- a particular advantage of the present invention is the excellent dose-response curve achieved for DNA transfer, which none of the prior art methods have achieved. One can thus obtain a level of transfection appropriate to the level of intra-tissue production or secretion desired. The process makes possible, finally, extra safety in relation to the chemical or viral methods of in vivo gene transfer, in which reaching organs other than the target organ cannot be totally ruled out and controlled.
- the process according to the invention makes possible the control of localization of the tissues transfected (strictly linked to the volume of tissue subjected to local electric pulses) and therefore introduces the possibility of suppressing transgene expression by the total or partial ablation of the tissue, which is possible because certain tissues are not critical or can regenerate, or both, as in the case of muscle. That great flexibility of use makes it possible to optimize the process according to the animal species (human and veterinary applications), the subject's age and his or her physiological and/or pathological condition.
- the process according to the invention further makes it possible, for the first time, to transfect large-sized nucleic acids, in contrast to viral methods, which are limited with respect to the size of a transgene by the size of the viral genome that can fit within the capsid.
- This possibility is essential for the transfer of very large-sized genes, like that of dystrophin or genes with introns and/or large-sized regulator elements, which is necessary, for example, for a physiologically regulated production of hormones. That possibility is essential for the transfer of artificial yeast episomes or chromosomes or minichrornosomes.
- Another object of the invention is linking of the electric pulses of a voltage field to compositions containing nucleic acids formulated with a view to any administration, making it possible to access the tissue by topical, cutaneous, oral, vaginal, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular, transdermal route, etc.
- the pharmaceutical compositions of the invention contain a pharmaceutically acceptable vehicle for an injectable formulation, notably, for a direct injection into the desired organ, or for any other administration. It can involve, in particular, sterile isotonic solutions or dry compositions, notably lyophilized, which, with addition, as the case may be, of sterilized water of physiological saline, make possible the composition of injectable solutions.
- the nucleic acid doses used for injection as well as the number of administrations and volume of injections can be adapted to different parameters and, notably, to the method of administration, the pathology involved, the gene to be expressed or even the duration of treatment sought.
- Target Tissues The present inventors have discovered that optimum conditions for gene transfer according to the invention differ depending on the target tissue. For example, an electric field of 200 volts/cm has been found to greatly enhance gene transfer into muscle cells. Under these conditions, significant gene transfer proceeds into tumor cells as well (in specific experiments, a 3-fold enhancement of gene transfer was observed), but gene transfer into tumor cells is much more efficient in an electric field of 400 volts/cm (2 log increase in gene transfer efficiency). In further experiments, an electric field strength of 500 volts/cm was optimum for gene transfer into tumor cells.
- a system or improved apparatus can be made for delivery of nucleic acids to muscle cells (and other large cells), and a system or improved apparatus having different electric field strength parameters can be developed for delivery of genes to tumor cells (and other small cells).
- a system or apparatus of the invention will generate a voltage gradient of between 1 and 400 volts/cm, preferably 4 to 400 volts/cm, more preferably 30 to 300 volts/cm. In specific embodiments, the voltage gradient is between 100 and 200 volts/cm. Particularly contemplated are systems or apparatus that provide a voltage gradient that does not exceed 200 volts/cm.
- a system or apparatus of the invention will generate a voltage gradient of between 1 and 600 volts/cm, preferably 100 to 600 volts/cm, more preferably 400 to 600 volts/cm.
- the voltage gradient is between 400 and 500 volts/cm, and preferably about 500 V/cm.
- Particularly contemplated are systems or apparatus that provide a voltage gradient that does not exceed 600 volts/cm.
- nucleic acids can be of synthetic or biosynthetic origin, or extracted from viruses or prokaryotic cells or eukaryotic cells originating from unicellular organisms ⁇ e.g., yeasts) or multicellular organisms. They can be administered linked in whole or in part to components of the original organisms and/or system of synthesis.
- the nucleic acid can be a deoxyribonucleic acid or a ribonucleic acid. It can involve sequences of natural or artificial origin and, notably, genomic DNA, cDNA, mRNA, tRNA and rRNA, hybrid sequences or synthetic or semisynthetic sequences of oligonucleotides, whether modified or not. Those nucleic acids can by obtained by any method known to the expert and, notably, by cloning, by chemical synthesis or even by mixed methods, including chemical or enzymatic modification of sequences obtained by cloning. They can be modified chemically.
- the nucleic acid can be a DNA or an RNA with sense or antisense or catalytic property like a ribozyme.
- Antisense refers to a nucleic acid having a sequence complementary to a target sequence, e.g. , an mRNA sequence whose expression it is sought to block by hybridization on the target sequence.
- Sense refers to a nucleic acid having a sequence homologous or identical to a target sequence, e.g. , a sequence linked to a protein transcription factor and involved in the expression of a given gene.
- the nucleic acid contains a gene of interest and elements making possible the expression of said gene of interest.
- the nucleic acid fragment is advantageously in the form of a plasmid.
- Deoxyribonucleic acids can be single or double-strand, like short oligonucleotides or longer sequences. They can carry genes, sequences regulating transcription or replication or regions of linkage to other cell components, etc. Such genes can include marker genes, i.e. , genes that produce a detectable marker to study cell function, migration, or gene function; a therapeutic gene; a protective antigen or immunogen gene; and the like. According to the invention, "therapeutic gene” refers, notably, to any gene coding for an RNA or for a protein product having a therapeutic effect.
- the coded protein product can be a protein, a peptide, etc.
- This protein product can be homologous with the target cell (that is, a product which is normally expressed in the target cell when it presents no pathology).
- the transgene expression makes it possible, for example, to overcome an inadequate expression in the cell or the expression of a protein inactive or weakly active by reason of a modification, or also makes it possible to overexpress said protein.
- the therapeutic gene can also code for a mutant of a cellular protein, having an increased stability, a modified stability, etc.
- the protein product can likewise be heterologous to the target cell.
- an expressed protein can, for example, complete or introduce a deficient activity in the cell (treatment of myopathies or enzyme deficiencies), or make it possible to fight against a pathology, or stimulate an immune response, for example, in the treatment of tumors. It can involve a suicide gene (thymidine kinase of he ⁇ es) for the treatment of cancers or restenosis.
- a suicide gene thymidine kinase of he ⁇ es
- the nucleic acid preferably includes also sequences making possible and/or favoring expression in the tissue of the therapeutic gene and/or gene coding for the antigenic peptide. It can involve sequences which are naturally responsible for the expression of the gene considered when those sequences are capable of functioning in the transfected cell. It can also involve sequences of different origin (responsible for the expression of other proteins, or even synthetic ones). Notably, it can involve eukaryotic or viral gene promoter sequences. For example, it can involve promoter sequences originating from the genome of the cell it is desired to transfect. Among the eukaryotic promoters, one can use an inducer or represser sequence to provide for specific expression of the gene.
- Ubiquitous (constitutive) promoters include HPRT, vimentin, ⁇ -actin, tubulin, etcl. promoters.
- Tissue-specific promoters include (elongation factor-1- ⁇ , fit, flk) may be used.
- Inducible promoters include promoters responsive to hormones (such as steroid receptors, retinoic acid receptors, etc.), or promoters regulated by antibiotics (tetracycline, rapamycine, etc.) or other natural or synthetic molecules. It can likewise involve promoter sequences originating from the genome of a virus.
- the nucleic acid can also contain, particularly above the therapeutic gene, a signal sequence directing the therapeutic product synthesized into the secretory ducts of the target cell.
- This signal sequence can be the natural signal sequence of the therapeutic product, but it can also involve any other functional signal, or an artificial signal sequence.
- the nucleic acid can also contain a signal sequence directing the synthesized therapeutic product to a particular cellular compartment, such as, for example, mitochondria for treatment of a mitochondrial genetic disease.
- Therapeutic Genes and Gene Products Among the therapeutic products according to the invention, one can particularly mention enzymes, blood proteins, hormones such as insulin or growth hormone, lymphokines: interleukins, interferons, tumor necrosis factors (TNF), etc. (French patent No. 92 03120), growth factors, e.g. , angiogenic factors such as VEGF or FGF.
- trophic factors For treatment of neuropathies, genes encoding neurotransmitters or their precursors or enzymes that synthesize neurotransmitters, trophic factors, particularly neurotrophic factors for the treatment of neurodegenerative diseases, damage to the nervous system caused by trauma or injury, or retinal degeneration, can be delivered with a system of the invention.
- members of the family of neurotrophic factors include, but are not limited to, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT3), NT4/5, NT6 (including allelic variants, and members of the same gene family).
- neurotrophins include members of the ciliary neurotrophic factor family, including ciliary neurotrophic factor (CNTF), axokine, leukemia inhibitory factor; other factors include IL-6 and related cytokines; cardiotrophin and its related genes; glial-derivcd neurotrophic factor (GDNF) and related genes; and members of the insulin-like growth factor (IGF) family, such as IGF-1, IFGF-2; members of the fibroblast growth factor family, such as FGF1 (acidic FGF), FGF2, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, etc.; members of the tumor growth factor family, such as TGF ⁇ ; HARP/pleiotrophin, or bone growth factors; hematopoietic factors, etc.
- CNTF ciliary neurotrophic factor
- axokine leukemia inhibitory factor
- other factors include IL-6 and related cytokines; cardiotrophin and its related genes; glial-derivc
- genes of interest code for muscle proteins of therapeutic benefit, both secreted and non-secreted, such as dystrophin or a minidystrophin (French patent No. 91 11947), or ⁇ -1- antitrypsin.
- genes of interest code for factors involved in coagulation: factors VII, VTH, IX; suicide genes (thymidine kinase, cytosine deaminase) ; hemoglobin genes or other protein carriers.
- genes corresponding to the proteins involved in lipid metabolism can be delivered, such as an apolipoprotein type chosen among the apolipoproteins A-I, A-II, A-IV, B, C-l, C-II, C-III, D, E, F, G, H, J and apo(a), and metabolic enzymes such as, for example, lipoprotein lipase, hepatic lipase, lecithin cholesterol acyltransferase, 7-alpha- cholesterol hydroxylase, phosphatidyl acid phosphatase, or even lipid transfer proteins like the transfer protein of cholesterol esters and the transfer protein of cholesterol esters and the transfer protein of phospholipids, an HDL-binding protein or even a receptor chosen, for example, among the LDL receptors, chylomicron remnant receptors and scavenger receptors, etc.
- leptin for the treatment of obesity.
- One can also add the p53 anti-oncogene or other tumor suppress
- angiogenic factors include vascular endothelial growth factors (VEGF, VEGF-2, VEGF-3, platelet growth factors), and angiostatin.
- delivery can be effected of genes encoding inhibitors of angiogenesis, particularly tumor angiogenesis, such as soluble receptors of angiogenic factors, specific inhibitors of the angiogenic factor receptors (Tie2, urokinase receptor, fltl, KDR), antibodies (including single chain Fv antibodies) against angiogenic factors ⁇ e.g., anti-VEGF or anti-FGF), anti-integrin antibodies, endotheliul tumor-specific toxins, polypeptide inhibitors of angiogenesis (amino terminal fragment of urokinase - ATF, angiostatin, endostatin, interferon- ⁇ or ⁇ , interleukin-12, platelet factor 4, TNF , thrombospondin, platelet activating factor (PAI)-l, PAI2,
- variable fragments of single-chain antibodies ScFv
- any other antibody fragment possessing recognition capacities for use in immunotherapy e.g., for the treatment of infectious diseases, tumors, and autoimmune diseases such as insular sclerosis (anti-idiotype antibodies).
- proteins of interest are, without limiting them, soluble receptors like, for example, the CD4 soluble receptor or the TNF soluble receptor for anti-HIV therapy, soluble TNF receptor (particularly soluble TNF ⁇ receptor) for treatment of rheumatoid arthritis, and the acetylcholine soluble receptor for the treatment of myasthenia; substrate peptides or enzyme inhibitors, or even receptor agonist or antagonist peptides or adhesion proteins like, for example, for the treatment of asthma, thrombosis, restenosis, metastases, or inflammation (for example LL-4 to diminish Thl cells responses, IL-10 and IL-13); and artificial, chimerical or truncated proteins.
- soluble receptors like, for example, the CD4 soluble receptor or the TNF soluble receptor for anti-HIV therapy, soluble TNF receptor (particularly soluble TNF ⁇ receptor) for treatment of rheumatoid arthritis, and the acetylcholine soluble receptor for the treatment of myas
- insulin in the case of diabetes, growth hormone and calcitonin.
- immunostimulatory cytokines including IL-2, IL-12, colony stimulating factors (GM- CSF, G-CSF, M-CSF), macrophage inflammatory factors (MIP1, MIP2), dendritic cell activating factors (flt3 ligand), etc.
- genes of interest have been described by McKusick, V.A. Mendelian (Inheritance in man, catalogs of autosomal dominant, autosomal recessive, and X-linked phenotypes. Eighth edition. Johns Hopkins University Press (1988)), and in Stanbury, J.B. et al. (The metabolic basis of inherited disease. Fifth edition, McGraw-Hill (1983)).
- the genes of interest cover the proteins involved in the metabolism of amino acids, lipids and other cell constituents.
- genes related to diseases of carbohydrate metabolism like, for example, fructose- 1 -phosphate aldolase, fructose- 1 ,6-diphosphatase, glucose-6-phosphatase, lysosomal a-l,4-glucosidase, amylo-l,6-glucosidase, amylo-(l,4:l,6)-transglucosidase, muscular phosphorylase, muscular phosphofructokinase, phosphorylase-b-kinase, galactose-1-phosphate uridyl transferase, all of the enzymes of the pyruvic dehydrogenase complex, pyruvic carboxylase, 2-oxoglutarate glyoxylase carboxylase, and D-glyceric dehydrogenase.
- fructose- 1 -phosphate aldolase fructose- 1 ,6-diphosphatase
- the genes related to diseases of amino acid metabolism like, for example, phenylalanine hydroxylase, dihydrobiopterine synthetase, tyrosine aminotransferase, tyrosinase, histidinase, fumarylaceto-acetase, glutathion synthetase, g-glutamylcysteine synthetase, ornithine-d-aminotransferase, carbamoylphosphate synthetase, omithine carbamoyltransf erase, argininosuccinate synthetase, arginosuccinate lyase, arginase, L-lysine dehydrogenase, L-lysine ketoglutarate reductase, valine transaminase, leucine isoleucine transaminase, branched-chain 2- keto-acid decarboxylase, isovaleryl-
- the genes related to diseases of fat and fatty acid metabolism like, for example, lipoprotein lipase, apolipoprotein C-II, apolipoprotein E, other apolipoproteins, lecithin cholesterolacetyltransferase, LDL receptor, liver sterol hydroxylase, and "phytanic acid" a- hydroxylase.
- lysosomal deficiencies like, for example, lysosomal a-L- iduronidase, lysosomal iduronate sulfatase, lysosomal heparan N-sulfatase, lysosomal N-acetyl- a-D-glucosaminidase, acetyl-CoA : lysosomal a-glucosamine N-acetyltransf erase, lysosomal N- acetyl-a-D glucosa ine 6-sulfatase, lysosomal galactosa ine 6-sulfate sulfatase, lysosomal ⁇ - galactosidase, lysosomal arylsulfatase B, lysosomal ⁇ -glucuronidase, N-acetylglucosaminyl-
- lysosomal aspartylglucosaminidase lysosomal a-L-fucosidase, lysosomal acid lipase, lysosomal acid ceramidase, lysosomal sphingomyelinase, lysosomal glucocerebrosidase and lysosomal galactocerebrosidase, lysosomal galactosylceramidase, lysosomal arylsulfatase A, a- galactosidase A, lysosomal acid ⁇ -galactosidase, and a chain of lysosomal hexosaminidase A.
- genes related to diseases of steroid and lipid metabolism the genes related to diseases of purine and pyrimidine metabolism, the genes related to diseases of po ⁇ hyrine and heme metabolism, and the genes related to diseases of connective tissue, muscle and bone metabolism as well as the genes related to diseases of the blood and hematopoiesis, muscles (myopathy), nervous system (neurodegenerative diseases) or circulatory system (treatment of ischemia and stenosis, for example).
- myopathy myopathy
- nervous system neurodegenerative diseases
- circulatory system treatment of ischemia and stenosis, for example.
- NT3 neurotrophin 3
- ALS amyotrophic lateral sclerosis
- Treatment of this insidious disease with NT3 gene therapy is expected to be greatly facilitated by delivering the NT3 by electrotransfer, which ensures adequate, reproducible expression of this trophic factor.
- aFGF acidic FGF
- VEGF vascular endothelial growth factor
- a therapeutic nucleic acid can also be a gene or an antisense sequence, whose expression in the target cell makes it possible to control the gene expression of cell mRNA transcription.
- Such sequences can, for example, be transcribed in the RNA target cell complementing cell mRNAs and thus block their protein translation, according to the method described in European patent No. 140,308.
- the therapeutic genes also include sequences coding for ribozymes, which are capable of selectively destroying target RNAs (European patent No. 321,201).
- Immunogenic Genes and Vaccines can also contain one or more genes coding for an immunogenic or an antigenic peptide, capable of generating an immune response in man or in the animal.
- the invention therefore makes possible vaccines or immunotherapeutic treatments applied to man or to the animal, notably, against microorganisms, viruses or cancers. It can involve, notably, specific antigenic peptides of the Epstein-Barr virus, HIV virus, hepatitis B virus (European patent No. 185,573), pseudo-rage virus, "syncitia forming virus,” other viruses or even specific antigens of tumors like MAGE proteins (European patent No. 259,212), or antigens capable of stimulating an antitumoral response, such as bacterial heat shock proteins.
- the nucleic acid can be linked to any type of vectors or any combination of those vectors making it possible to enhance gene transfer, e.g. , without limitation, to vectors such as viruses, synthetic or biosynthetic agents ⁇ e.g., lipid, polypeptide, glycoside or polymer), or even balls, propelled or not.
- the nucleic acids can also be injected into a tissue which has undergone a treatment aimed at enhancing gene transfer, e.g. , a treatment of a pharmacological nature in local or systemic application, or an enzyme, permeabilizing (use of surfactants), surgical, mechanical, thermal or physical treatment.
- a treatment aimed at enhancing gene transfer e.g. , a treatment of a pharmacological nature in local or systemic application, or an enzyme, permeabilizing (use of surfactants), surgical, mechanical, thermal or physical treatment.
- EXAMPLE 1 STANDARD ELECTROPORATION CONDITIONS Standard electroporation condition, e.g., as employed in the US Patent Nos. 5,468,223,
- DNA pXL2774 (PCT/FR patent 96/01414) is a plasmid DNA containing the reporter gene of luciferase.
- the other products are available at suppliers' on the market: ketamine, xylazine, physiological saline (NaCl 0.9%).
- mice were anesthetized with a ketamine and xylazine mixture.
- the plasmid solution (30 mg/ml of a solution with 500 mg/ml of NaCl 0.9%) was injected longitudinally through the skin into the cranial tibial muscle of the left and right paws by means of a Hamilton's syringe.
- the two electrodes were coated with a conductive gel and the paw injected was placed between the electrodes in contact with the latter.
- the electric pulses were applied pe ⁇ endicular to the axis of the muscle by means of a square pulse generator one minute after the injection.
- An oscilloscope made it possible to check the intensity in volts (the values indicated in the examples represent maximum values), the duration in milliseconds and the frequency in hertz of the pulses delivered, which was 1 Hz. Eight consecutive pulses were delivered.
- mice were euthanized seven days after administration of the plasmid.
- the cranial tibial muscles of the left and right paws were then removed, weighed, placed in the lysis buffer and ground.
- the suspension obtained was centrifuged in order to obtain a clear supernatant.
- Measurement of luciferase activity was carried out on 10 ml of supernatant by means of a commercial luminometer, in which the substrate was added automatically to the solution.
- the intensity of the luminous reaction is given in RLU (Relative Luminescence Units) for a muscle experiencing the total volume of suspension.
- RLU Relative Luminescence Units
- EXAMPLE 2 ELECTROTRANSFER OF NUCLEIC ACIDS This experiment was carried out with C57 Bl/6 mice. Apart from the electric field intensity of the pulses and their duration, the performance conditions were those of Example 1. The results are shown on Figure 2. The result of Example 1 was reproduced, that is, the inhibiting effect of a series of 8 pulses at 800 volts/cm with duration of 1 msec on the luciferase activity detected in the muscle. With a field of 600 volts/cm, the same inhibition and the same alteration of the muscular tissue was observed. However, shorter pulse widths at this voltage are likely to avoid tissue damage while enhancing DNA transfer.
- the transgene expression was enhanced by a factor of 89.7 in relation to the control injected in the absence of electric pulses.
- EXAMPLE 4 200-FOLD INCREASE IN EXPRESSION This experiment was carried out in DBA 2 mice with electric pulses of 200 volts/cm of variable duration. The other conditions of this experiment are the same as in Example 3. This example confirms that at 200 volts/cm the transfection of luciferase activity increased when the pulse duration was increased from 5 msec to longer duration ( Figures 4 and 5) . A reduction of the interindividual variability indicated by the SEM in relation to the control not electrotransfected was observed. The relative value of the SEM is equal to 35% for the control and 25, 22, 16, 18, and 26% for series of pulses of 1, 5, 10, 15, 20 and 24 msec respectively. Under the optimal conditions used in this experiment, the transgene expression was enhanced by a factor of 205 in relation to the control injected in the absence of electric pulses. These results confirm that electrotransfer under the conditions described in these examples greatly improves both efficacy and reproducibility.
- Figure 5 exemplifies the importance of the parameter corresponding to the product "number of pulses x field intensity x duration of each pulse.” That parameter corresponds, in fact, to the integral dependent on time of the function which describes the variation of the electric field.
- mice mice, rats, rabbits.
- Electric pulses have to be administered after DNA injection and at the same site.
- the DNA vector can be administered up to 30 min before the pulse without noticeably decreasing the response. This allows multiple DNA injections at nearby sites followed by one single pulse.
- Electrotransfer efficiency does not depend in any way on the transgene promoter, which permits another level of control of gene expression.
- the presence of secretory or other regulatory/processing sequences in the gene product has no effect on electrotransfer efficiency.
- EXAMPLE 7 TRANSFECTION AS A FUNCTION OF PULSE DURATION This example demonstrates the effect of increasing the pulse duration on transfection efficiency under electrotransfer conditions.
- the experimental conditions were the same as those of Example 1 with C57B1/6 mice, except that a Gentronics/BTX T820 pulse generator (BTX, a division of Genetronics, San Diego, California) was used.
- the BTX pulse generator enabled application of square pulses of durations up to 100 ms.
- Plasmid pXL2774 (WO 97/10343) was injected (15 ⁇ g). It is noted in Table 1 that at a constant electric field strength of 200 V/cm, increasing the duration (T) of the pulses improves the efficiency of the transfection.
- Such a device preferably provides a pulse of 20 msec or greater, with at least 4, and more preferably 8, pulses.
- Electrotransfer conditions 200 V/cm field strength, 1 Hz frequency.
- a device for electrotransfer under the optimized field strength described in this application can further enhance the efficiency of DNA transfer by increasing the duration of the pulse. For example, increasing the duration to at least 40 msec with a series of 8 pulses, or 50 msec for a series of 4 pulses, significantly enhanced transfection efficiency at 200 V/cm. Similar optimizations of the device can be effected for other field strength.
- EXAMPLE 8 TRANSFECTION AS A FUNCTION OF THE NUMBER OF PULSES
- Example 2 The experimental conditions were the same as described in Example 1, using C57B1/6 mice. Table 2 shows that at 200 V/cm with a pulse duration of 20 ms, the efficiency of the transfection was clearly improved compared to the control group (no electric field applied), starting from a single pulse, then continues to increase when the number of pulses is increased to 2, 4, 6, 8, 12, and 16, with the optimum between 8 and 16 pulses. Also to be noted is a reduction in the variance (S.E.M.) for all the electrotransfected groups compared to the control (0 pulses).
- S.E.M. variance
- an electrotransfer device enhances the efficiency of DNA transfer with more pulses.
- a device optimally provides 4 or more, and better yet, 8 or more, pulses.
- an electrotransfer device can modulate the efficiency of nucleic acid transfer, and thus adjust the level of expression.
- EXAMPLE 10 ELECTROTRANSFECTION WITH AN EXPONENTIALLY DECREASING TIME- VARYING ELECTRIC FIELD. This example shows the effect of application of an electric field that decreases exponentially on the efficiency of nucleic acid transfer in vivo.
- Plasmid pXL3031 ( Figure 12), derived from plasmid pXL2774 by introducing modified Photinus pyralis luciferase (pGL3; Genbank accession no. CVU47295) under control of the cytomegalovirus immediate early (CMV-EE) promoter (Genbank accession no. HS5LEE) and a polyadenylation signal from SV40 virus (Genbank accession no. SV4CG), was used in this experiment. Ten ⁇ g of DNA were injected.
- CMV-EE cytomegalovirus immediate early
- the commercial electropulser (Equibio electropulsater, model EasyjectT “ Plus, Kent, UK) used here was configured to deliver exponentially decreasing time-varying electric field pulses.
- the recorded voltage applied is the voltage at the peak of the exponential.
- the second adjustable parameter is the capacitance (in ⁇ F), which controls the quantity of energy delivered.
- Table 4 shows that, when an exponentially decreasing field pulse is applied, it is possible to obtain a very clear increase in the expression of the transgene compared to the case when no field is applied. This result is obtained at different voltages and for different energies corresponding to different time constants of the exponential, which may be modulated by the adjustable capacitance of the instrument.
- the parameters established in this example can be applied to an electrotransfer device.
- EXAMPLE 11 COMBINATION OF A SHORT HIGH- VOLTAGE PULSE AND SEVERAL
- the electric field delivered may be a combination of at least one strong field between 500 and 800 V/cm for a short period, for example 50 or 100 us, and at least one weak field ( ⁇ 100 V/cm) for a longer time, for example, more than 1 ms up to 90 ms in this experiment.
- the weak electric field values here are 80 V/cm applied in 4 pulses at 1 Hz with a duration of 90 ms each.
- two commercial electropulsaters were used (Jouan and Gentronix). The delivery of the electrical voltage by one and then the other instrument to the electrode plates occurs in less than one second by modifying the operation con iguration manually.
- the luciferase-encoding plasmid used here was pXL3031 and the quantity injected was 3 ⁇ g.
- the values for the electric field strength were varied, as reported in Table 5. Otherwise, the experimental conditions were the same as described in Example 1.
- Table 5 summarizes the experiments. These data indicate that, compared to the control group (no electric field applied), one short high-voltage pulse or 4 long low- voltage pulses, or the application of weak electric field pulses before the high field pulse, did little to improve transfection efficiency. In contrast, in the experiments, the combination of a short high voltage pulse followed by 4 pulses of 80 V/cm of 90 ms duration at 1 Hz very clearly increased transfection compared to the control group. From these data, it appears that a preferred electrotransfer device would supply a series of shorter pulses at higher electric field strength
- Example 1 As shown in Example 1, supra, application of 8 pulses of 600, 800, or 1200 V/cm for 1 msec at a frequency of 1 Hz caused muscle lesions and inhibited transfection.
- the results obtained in this Example show that, under the specified conditions, it is possible to use an high voltage electric field without causing lesions. Indeed, macrospopic examination of the muscle did not evidence any visible atleration.
- Use of a high voltage field for a short time, followed by weak fields for longer time periods, provides an alternative means for modulating the efficiency of DNA transfer.
- EXAMPLE 12 KINETICS OF LUCIFERASE EXPRESSION IN MUSCLE Use of an electrotransfer device of the application permits transfection and stable expression of a nucleic acid at a high level for at least four months.
- mice C67B1/6 mice were used in this experiment.
- the mice were injected intramuscularly with plasmid pXL2774 (15 ⁇ g). Injection of the DNA was followed by application of an electric field under the following conditions: 200 V/cm; 8 pulses of 20 msec duration; 1 Hz frequency. Other conditions were as described in Example 1. Luciferase activity was determined for groups of 10 mice sacrificed at different times after injection of the DNA. Control mice were not exposed to the electric field.
- the level of expression of the transgene was stable to D121. This result is especially advantageous from the perspective of long term clinical treatment with therapeutic genes.
- the pXL2774 plasmid was modified by introduction of the lacZ gene modified with a nuclear localization signal sequence (see Mouvel et al, 1994, Virology 204:180- 189) under control of the CMV promoter obtained from plasmid pCDNA3 (Invitrogen, Netherlands), with the SV40 polyadenylation signal (Genbank accession no. SV4CG).
- the animals were sacrificed seven days after administration of the plasmid. Histologic analysis allowed detection of ⁇ -galactosidase transfected cells (Xgal histochemistry) and the inflammatory foci by alumized carmine staining and the characterization of the muscle tissue condition by hematein-eosin staining. Control mice were not exposed to the electric field. The differences between the electropermeabilized and non-electropermeabilized muscles were shown by:
- the expression area of ⁇ -galactosidase was 2 times larger in the electropermeabilized muscles (4 mm) compared to controls, with an expression gradient which decreases from the injection site. •
- the electropermeabilized muscles present a reversible number of infiltrates (macrophages and lymphocytes), numerous muscular fibers in regeneration with a nuclear centralization, and numerous necrotic fibers filled with phagocytic macrophages.
- the inflammation, necrosis, and regeneration zone corresponds to the zone around the transfected myofibrils. This response lasted up to two weeks, and reversed itself. The non-transfected part of the muscle remains in good condition.
- EXAMPLE 14 ROLE OF TIME OF INJECTION OF THE PLASMID RELATIVE TO THE TIME OF APPLICATION OF THE ELECTRICAL FIELD
- nucleic acid can be injected into tissue (in this case, muscle) at least 30 minutes, and even as long as one hour, prior to application of the electric field.
- C57B1/6 mice were injected intramuscularly with plasmid pXL2774 (15 or 1.5 ⁇ g).
- the DNA was injected up to 120 minutes before or 60 seconds after the electric field was applied.
- the time before or after injection is reported in Table 6.
- the electric field conditions used were: 200 V/cm; 8 pulses of 20 msec duration; 1 Hz frequency.
- Control mice received an injection of the plasmid but were not exposed to the electric field.
- Other experimental conditions were the same as those of Example 1.
- the data are reported in Table 6. Injection of the DNA up to one hour prior to application of the electric field resulted in achievement of increased transfection efficiency, as detected by luciferase expression.
- mice Five-week-old C57BI16 mice were injected intramuscularly bilaterally in the tibial cranial muscles with doses varying from 0.25 to 32 ⁇ g of DNA (plasmid pCOR-pXL3031) bearing the transgene luciferase for cytoplasmic expression, under the promoter CMVh at a rate of 10 mice per dose of DNA.
- the dose of DNA varied from 0.25 to 32 ⁇ g.
- one of the two legs was exposed to a field of 250 V/cm, with 4 pulses of 20 ms at a frequency of 1 Hz.
- the animals were sacrificed 5 days after the treatment and the expression of the transgene was studied in the tissue extract of each muscle according to the protocol described in Example 1.
- EXAMPLE 16 ELECTROTRANSFER WITH DIFFERENT ELECTRODES
- This Example compares the effect of electrotransfer devices equipped with one of two types of electrodes, flat plate electrodes and needle electrodes, on the efficiency of nucleic acid transfer.
- needle electrodes were tested in different orientations of implantation. Plasmid pXL2774 (150 ⁇ g) was injected in the tricep muscle of the rat. The plate electrodes were placed as described in Example 1 at an inter-electrode distance of 1.2 cm. For the needle electrodes, the inter-electrode distance was 0.9 cm. The needle electrodes were inserted for an equal length in the muscle tissue, either parallel to or perpendicular to the axis of the muscle fibers around the injection site. Regardless of the type of electrodes or their orientation, the electric field conditions were as follows: intensity of 200 V/cm; 8 pulses of 20 msec; frequency of 2 Hz.
- an electrotransfer device can employ either plate or needle electrodes, regardless of the electrode orientation relative to the target tissue.
- Use of needle electrodes may be preferred to administer nucleic acids to muscles of large size to ensure that the total voltage is moderate, for example 100 V with placement of the needle electrodes within 0.5 cm for an electric field strength of 200 V/cm.
- the plate electrodes which are noninvasive, may be preferred with small muscles, e.g., the fingers, such as for delivery of a gene therapy for arthritis.
- EXAMPLE 17 ELECTROTRANSFER INTO DIFFERENT MUSCLES AND SPECIES
- This Example illustrates that the electrotransfer device can be used to effect nucleic acid transfer into many different types of muscles in different species of animals.
- the electrotransfer device was adjusted to provide the conditions for each species as defined in Table 8. The results are shown in Table 8 as well.
- the relative increase in the level of luciferase expression using an electrotransfer device relative to control (no electrotransfer) is indicated.
- the data are the average of 10 muscles per group. Luciferase activity was determined seven days after administration of the plasmid.
- Figure 11 comprising a gene encoding fibroblast growth factor 1 (acidic fibroblast growth factor) (FGF1 or aFGF) was derived from plasmid pXL2774 in which the human fibroblast interferon signal peptide was fused to cDNA for aFGF (sp-FGFl, Jouanneau et al. , 1991, PNAS 88:2893-2897) was introduced under control of the human CMV-IE promoter and the SV40 polyadenylation signal.
- aFGF expression was determined by immuno-histochemistry. The number of positive cells (cells expressing aFGF) were evaluated three days after intramuscular injection with 500 ⁇ g of plasmid pXL3179.
- an electrotransfer device of the invention to provide for long term, stable expression of a transgene has important implications in the treatment of degenerative diseases that affect function of the diaphram, notably muscular dystrophy.
- the diaphragm was rendered accessible by an incision along the sternum after anesthesia (mixture of 1 mg/kg largactyl and 150 mg/kg ketamine).
- the injection was made in the hemidiaphragm (50 ⁇ g of plasmid pXL2774 in 50 ⁇ l of NaCl 20 mM and glucose 5%).
- the plate electrodes were then placed one on either side of the plane of the diaphragm along the injection path at an inter-electrode distance of 1 mm.
- the electric field conditions used were as follows: 160 V/cm or 300 V/cm; 8 pulses of 20 msed duration each; 1 Hz frequency.
- the electric field was applied to the muscle less than one minute after the injection.
- the incision in the animal was then closed.
- Table 10 The results are shown in Table 10.
- Table 10 Electrotransfer into rat diaphragm muscle.
- This example demonstrates a significant amelioration of expression of the transgene in the diaphram after application 820 msec pulses at a field strength of 160 V/cm (p ⁇ 0.003 using the Mann- Whitney non parametric test).
- EXAMPLE 20 ELECTROTRANSFER OF A SECRETED ALKALINE PHOSPHATASE GENE This example demonstrates the ability to transfect and express a gene encoding a secreted protein.
- Secreted proteins are used, for example, in a systemic gene therapy approach, and for generating an immune response (DNA vaccine).
- the secreted gene presented here was found in the circulation at an elevated concentration, and its presence was stable.
- the alkaline phosphatase-encoding plasmid pXL3010 ( Figure 13) was injected into one of the two tibial cranial muscles of an adult C57B1 6 mouse.
- the plasmid pXL3010 was derived from ColEl in which the gene coding for secreted alkaline phosphatase (SeAP) from pSEAP-basic (Clontech; Genbank accession no. CVU09660) was introduced under control of the CMV promoter (pCDNA3; Invitrogen, Netherlands) and the SV40 polyadenylation signal.
- the application of the electric field was performed under standard conditions, i.e., 8 square pulses of 20 msec duration, 1 Hz frequency, and 200 V/cm applied 20 seconds after injection of the plasmid.
- Measurement of the concentration of the blood serum serum alkaline phosphatase was carried out on a blood sample from the eye (retro-orbital plexus puncture) 7 days later using a commercial chemiluminescence assay (Phosphalight, Tropix, Bedford, Massachusetts, US).
- the injection of a few muscles subjected or not to the electric field with a non-encoding plasmid (ballast DNA) allowed verification of the absence of serum alkaline phosphatase that does not come from the expression of the transgene.
- This example demonstrates that a therapeutic gene can be transferred to muscle using an apparatus of the invention, and that expression of the gene product effects a detectable and meaningful physiologica response.
- the expression of erythropoietin can be detected, and the expressed protein induces an increase in the hematocrit of the recipient animal.
- C57B1/6 mice were injected in the tibial cranial muscle unilaterally with plasmid pXL3348 (Figure 16), comprising the gene coding for erythropoietin.
- the plasmid pXL3348 was derived from plasmid pXL2774 by introducing the murine erythropoietin gene (NCBI: 193086) under control of the human CMV-EE promoter and SV40 polyadenylation signal.
- the electric field 200 V/cm, 8 pulses of 20 msec duration, 1 Hz frequency was applied immediately after injection of the plasmid.
- the injection of 1 ⁇ g of plasmid was associated with a moderate increase of the hematocrit for mice conventionally transfected, and was very high for the electrotransfected mice.
- the hematocrit increased for the control group.
- the electrotransfected group the hematocrit was clearly greater, with less variance. Similar results were observed with a lower amount of DNA (1 ⁇ g).
- EXAMPLE 22 ELECTROTRANSFER OF VEGF (VASCULAR ENDOTHELIAL GROWTH FACTOR) GENE
- Plasmid pXL3212 was derived from plasmid pXL2774 by introducing the cDNA coding for VEGF (Genbank accession no. HUMEGFAA) under control of the human CMV-ES promoter and the SV40 polyadenylation signal. The electrotransfection was carried out using a commercial electropulser (Jouan) at a rate of 8 pulses of 20 msec duration, 200 V/cm, at a frequency of 2 Hz.
- Serum concentration (ng/liter) of VEGF in C57B1/6 and SCID mice was obtained from mice one day prior to injection of the plasmid.
- the experimental conditions were the same as in Example 22, except that 15 ⁇ g of the clotting factor IX-encoding plasmid pCor hFIX (pXL3388; Figure 12) was injected per muscle in C57BL6 or SCID mice.
- the pXL3388 plasmid was derived from plasmid pXL2774 by introducing the cDNA encoding human factor IX (Christmas factor; Genbank accession no. HUMFLXA) under control of the CMV-LE promoter and SV40 polyadenylation signal.
- the electrotransfer conditions were as follows: 8 pulses of 20 msec duration at 200 V/cm, 2 Hz frequency. Factor IX levels were measured seven days after injection of the plasmid. Blood samples were taken from the retro-orbital plexus in tubes containing trisodium citrate, and the tubes stored in ice.
- Table 14 shows that the human factor IX was found only in the blood of mice C57BL6 and SCID whose tibial cranial muscles were injected with pXL3388 plasmid and subjected to the application of an electric field using an electrotransfer apparatus of the invention.
- Human factor IX is not detectable in mouse blood in the absence of use of an electrotransfer apparatus of the invention.
- EXAMPLE 24 ELECTROTRANSFER OF AN ACIDIC FIBROBLAST GROWTH FACTOR (aFGF) GENE
- the experimental conditions are like those in Example 22, except for the fact that 15 ⁇ g of the FGF-encoding plasmid pCor CMV a FGF (pXL3096; Figure 14) was injected per muscle in C57BL6 or SCID mice.
- the pXL3096 plasmid was derived from plasmid pXL2774 by introduction of a triple helix forming sequence (TH; Wils et al, 1997, Gene Ther.
- the number of fibers expressing FGF in randomly-selected sections was always clearly superior for the electrotransfected muscles than for the control muscles, which received only an injection of the ⁇ XL3096 plasmid alone.
- the expression of FGF after electrotransfection reaches a maximum at D8.
- D21 and D35 the presence of FGF for the control groups is virtually undetectable whereas a large number of positive fibers were observed in the electrotransfected groups.
- the number of aFGF positive fibers, detected by immunohistochemistry, in a muscle section were determined for individual mice.
- the muscle sections were obtained from the middle of the muscle.
- aFGF as determined by the number of positive fibers revealed by immunohistochemistry, was detected almost exclusively in mice that had received treatment with an electrotransfer apparatus. Moreover, aFGF expression was detectable at the lower DNA dose as well as the higher dose.
- EXAMPLE 25 ELECTROTRANSFER OF A NEUROTROPHIC FACTOR-3 (NT3) GENE
- NT3 NEUROTROPHIC FACTOR-3
- Thepmn mice are a model for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) characterized by an early and rapid degeneration of motoneurons and by an average life expectancy of about 40 days.
- ALS amyotrophic lateral sclerosis
- Plasmid pXL3149 was derived from plasmid pXL2774 by introduction of the murine NT3 gene (Genbank accession no. MMNT3) under control of the human CMV-IE promoter and the SV40 polyadenylation signal. The expression -of the NT3 was studied in the supernatant prepared by centrifugation (12,000 x g) of the ground muscle in PBS buffer 7 days after the treatment of the mice, and quantified by an ELISA assay (Promega Kit). With the C57B1/6 mice received injections of 12.5 ⁇ g of plasmid DNA.
- mice Half of the mice were subjected to an electric field (250 V/cm with 4 pulses of 20 ms at a frequency of 1 Hz) immediately after injection.
- the respective 95% confidence intervals calculated for an average of 20 muscles are 77 ⁇ 11 pg/muscle when there was no electrotransfer and 2.7 ⁇ 0.9 ng/muscle with electrotransfer.
- the endogenous NT3 level was not determined.
- Similar data were found for expression of NT3 in 4 to 5 day old Xtlpmn heterozygous mice. These mice received injections of 130 ⁇ g of DNA per animal after multisite injection in different muscles (gastrocnemien, 25 ⁇ g; tibial cranial muscle, 12.5 ⁇ g).
- NT3 a basal level of NT3 was detected in the gastrocnemien and tibial cranial muscles.
- injection of plasmid pXL3149 increases the level of NT3 expression.
- utilization of an apparatus of the invention to increase transfection efficiency greatly increases the amount of transgene product expressed, both in the muscle and in plasma. This increase is especially important for NT3 expression, to achieve a neurotrophic gene therapy.
- EXAMPLE 26 ELECTROTRANSFER OF A FOR HUMAN GROWTH HORMONE GENE
- Plasmid pX13353 is derived from plasmid pXL2774 by introduction of a genomic human growth hormone gene (fragment Xbal Sph of hGH that extends from the transcription initiation signal to a BamHI site, which is 224 basepairs after the polyadenylation signal) under control of the human CMV-IE promoter and the SV40 polyadenylation signal.
- the hGH cDNA was obtaned by reverse transcription from a human pituitary mRNA library after 30 cycles of amplification using the following primers: 5' complementary oligo:
- This oligonucleotide contains a kozak Xbal sequence.
- This oligonucleotide contains an Nsil site and the stop codon.
- the amplified fragment was cloned into plasmid pCR2.1 (TA Cloning Kit, Invitrogen) and sequenced.
- An Xbal/Nsil fragment of 681 basepairs containing the hGH cDNA was ligated with the Xbal Nsil fragment of pSL3353 to generate plasmid pXL3354.
- Electrotransfer conditions were as follows: 200 V/cm; 8 pulses of 20 msec duration; 1 Hz frequency. The electric field was applied immediately after injection of the plasmid DNA. The presence of hGH was detected seven days after treatment of the mice in ground muscle supernatant in buffered PBS after centrifugation at 12,000 x g. The quantity of hGH was measured by ELISA (Boehringer Manheim).
- This Example reports that an apparatus for electrotransfer of the invention enhances delivery of genes for gene (or DNA) vaccination.
- the following products were used: VR-HA, a plasmid DNA including the gene of the hemagglutinin of the flu virus (strain A/PR/8/34).
- mVRgBDT is a plasmid DNA including the gene of the glycoprotein B (gB) of the human cytomegalovirus (Towne strain).
- the other products are available from commercial suppliers: Ketamine, Xylazine and physiological sodium chloride solution (NaCl 0.9%).
- the experiment was performed in 9- week-old female mice Balb/c. Mice originating in different cages were distributed randomly before the experiment (randomization).
- An oscilloscope and a commercial generator of electrical pulses (rectangular or square) (Electropulser PS 15, Jouan, France) were used.
- the electrodes used were stainless steel flat electrodes spaced 5 mm apart.
- the mice were anesthetized using a mixture of ketamine and xylazine.
- the plasmid solution (50 ⁇ l of a solution at 20 ⁇ g/ml or 200 ⁇ g/ml in NaCl 0.9%) was injected longitudinally through the skin into the tibial cranial muscle of the left leg using a Hamilton syringe.
- the two electrodes are coated with a conductive gel and the injected leg was placed between the electrodes in contact with them.
- the electrical pulses were applied perpendicularly to the axis of the muscle using a square pulse generator, 20 seconds after the injection.
- Antibody titers directed against flu hemagglutinin obtained after injection of 1 or 10 ⁇ g of VR-HA DNA in the absence (-) or presence (+) of an electric field provided by an electrotransfer apparatus.
- the value (p) was obtained by comparison two by two of the groups injected with DNA, then treated or not with the electric field using the non parametric Mann- Whitney test.
- Antibody titers directed against CMV glycoprotein B obtained after injection of 10 ⁇ g of VR-gB DNA in the absence (-) or presence (+) of an electric field provided by an electrotransfer apparatus.
- the value (p) was obtained by comparison two by two of the groups injected with DNA, then treated or not with the electric field using the non parametric Mann-Whitney test.
- EXAMPLE 28 ELECTROTRANSFER APPARATUS FOR TRANSFECTION OF TUMOR CELLS
- Example illustrates use of an electrotransfer apparatus to enhance delivery of nucleic acids into tumor tissue.
- an electrotransfer apparatus of the invention to provide higher voltages than are preferred for electrotransfer of nucleic acids into muscle, efficient transfection of tumor cells (and most other cells) in vivo can be effected.
- This example demonstrates effects of electrotransfer on different tumors of either human origin implanted on nude (immunodeficient) mice, or of murine origin implanted on C57B1/6 (immunocompetent) mice.
- the effects of low-intensity electric-field pulses have been demonstrated: A) on plasmid DNA transfection by intratumoral injection, and B) on secretion of a protein encoded by a transgene into plasma following intratumoral injection.
- Tumor grafts were implanted on one side of either female nude or C57B3/6 mice weighing 18-20 g.
- Human lung carcinoma (HI 299) or colon adenocarcinoma (HT29) tumors of 20 mm 3 were implanted in nude mice.
- Murine fibrosarcoma (LBP) cells (10 6 cells), or melanoma (B16) or lung carcinoma (3LL) tumors (20 mm 3 ) were implanted in C57B1/6 mice. The mice were classified according to the size of their tumors and divided into homogeneous lots.
- mice were anesthetized with a mixture of ketamine and xylazine.
- Either plasmid pXL3031 (cytoplasmic luciferase) or pXL3010 (secreted alkaline phosphatase) were injected intratumorally after the tumors reached the target volume.
- the plasmid solution (40 ⁇ l of a 250 ⁇ g ml solution of DNA in 20 mM NaCl, 5% glucose) was injected lengthwise into the center of the tumor with a Hamilton syringe.
- the lateral surfaces of the tumor were coated with a conductive gel and the tumor was placed between the two electrodes. Electrical pulses were applied using a square pulse generator, 20 to 30 seconds after the injection.
- An oscilloscope controlled the voltage intensity, the duration in milliseconds and the frequency in hertz of the 8 pulses delivered at 200 to 800 volts/cm, 20 msec and 1 hertz.
- An oscilloscope and a commercial electric-pulse (rectangular or square) generator (Electro-pulsateur PS 15, Jouan, France) were used.
- the electrodes were stainless steel plate electrodes separated by 0.45 to 0.7 cm.
- mice (generally 10 mice per experimental group, depending on conditions) were euthanized 2 days after the injection of the plasmid.
- the tumors were removed, weighed, and crushed in a lysis buffer.
- the suspension obtained was centrifuged to obtain a clear supernatant.
- Luciferase activity was measured in 10 ⁇ l of supernatant using a commercial luminometer in which the substrate was added automatically. The results were expressed in total RLUs (Relative Light Units) per tumor.
- Plasma levels of secreted alkaline phosphatase (SeAP) were measured as described in Example 20, supra, at days 1, 2, and 8 (Dl, D2, D8) after injection of the DNA.
- Results and Discussion Electrotransfer into a human lung carcinoma tumor.
- the conditions generally used for intramuscular gene electrotransfer were used: an electric field of 200 v/cm, 8 pulses at a frequency of 1 hertz, and the results obtained were compared with those obtained at higher voltages ranging from 300 to 500 volts/cm.
- the purpose of a second experiment was to determine the optimal voltage conditions that must be applied to obtain maximum transfection, or voltages ranging from 400 to 800 volts/cm. The results are shown in Table 20.
- Plasmid pXL3031 was injected into H1299 human lung carcinoma tumors that had reached the target volume of 200-300 mm 3 in female nude mice. Average values of luciferase expression with the SEM are reported.
- Electrotransfer into a human colon adenocarcinoma tumor The results of the two experiments are illustrated in Table 2.
- Table 2 the application of an electrical field with an intensity of 600 volts/cm made it possible to reach an optimal rate of transfection regardless of the transfection level without electrotransfer.
- Transfection was improved by a factor of 6 to 23-fold, respectively, and it was relatively similar from 400 to 600 volts/cm.
- Table 21 Electrotransfer into a human colon adenocarcinoma tumor
- Plasmid pXL3031 was injected into HT29 human colon adenocarcinoma tumors that had reached the target volume of 100-200 mm 3 in female nude mice. Average values of luciferase expression with the SEM are reported. The inter-electrode distance in this experiment was 0.45 cm.
- Electrotransfer into a murine fibrosarcoma tumor The results of two experiments are illustrated in Table 22. Compared to the control groups without electrotransfer, the application of an electrical field with an intensity of 300 to 600 volts/cm improved gene transfer by a factor of 30 to 70-fold, regardless of the voltage applied.
- Table 22 Electrotransfer into a murine fibrosarcoma tumor.
- Plasmid pXL3031 was injected into murine LPB fibrosarcoma tumors that had reached the target volume of 100-200 mm 3 in female C57B]/6 mice. Average values of luciferase expression with the SEM are reported.
- Electrotransfer of murine melanoma tumors The results are illustrated in Table 23. Compared to the control group without electrotransfer, the application of an electrical field with an intensity of 500 volts/cm improves gene transfer by a factor of 24-fold.
- Table 23 Electrotransfer of murine melanoma tumors.
- Plasmid pXL3031 was injected into murine B16 melanoma tumors that had reached the ttaarrggeett vvoolluummee ooff 220000--330000 r mr m 3 in female C57B1 6 mice. Average values of luciferase expression with the SEM are reported.
- Plasmid pXL3031 was injected into murine 3LL lung carcinoma tumors that had reached the target volume of 30 mm 3 after 5 days of growth in female C57B1/6 mice. Average values of luciferase expression with the SEM are reported.
- Table 25 Electrotransfer of a secreted transgene into a human lung carcinoma tumor
- Plasmid pXL3010 (expressing SeAP) was injected into human H1299 lung carcinoma tumors that had reached the target volume of 200-300 mm 3 in female nude mice. Average values of luciferase expression with the SEM are reported. A single electric field of 500 V/cm was applied, and the level of SeAP in plasma detected 1, 2, and 8 days after injection of the plasmid.
- an anti-angiogenesis gene such as the amino terminal fragment of urokinase (ATF) or angiostatin (or endostatin) would also be an effective tumor gene therapy.
- ATF amino terminal fragment of urokinase
- angiostatin or endostatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9708232A FR2765241B1 (fr) | 1997-06-30 | 1997-06-30 | Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede |
FR9708233 | 1997-06-30 | ||
FR9708233A FR2765242B1 (fr) | 1997-06-30 | 1997-06-30 | Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede |
FR9708232 | 1997-06-30 | ||
US6748897P | 1997-12-01 | 1997-12-01 | |
US6748797P | 1997-12-01 | 1997-12-01 | |
US67488P | 1997-12-01 | ||
US67487P | 1997-12-01 | ||
US8385898P | 1998-05-01 | 1998-05-01 | |
US83858P | 1998-05-01 | ||
PCT/EP1998/003976 WO1999001175A1 (en) | 1997-06-30 | 1998-06-30 | Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0993318A1 true EP0993318A1 (de) | 2000-04-19 |
Family
ID=27515625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98938676A Ceased EP0993318A1 (de) | 1997-06-30 | 1998-06-30 | Vorrichtung zur optimierten elektrotransfer der nukleinsäuren vektoren an gewebe in vivo |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0993318A1 (de) |
JP (1) | JP2002515816A (de) |
KR (1) | KR20010014298A (de) |
CN (1) | CN1261812A (de) |
AU (1) | AU8730798A (de) |
BR (1) | BR9810500A (de) |
CA (1) | CA2295029A1 (de) |
IL (1) | IL133709A0 (de) |
NO (1) | NO996540L (de) |
PL (1) | PL337617A1 (de) |
WO (1) | WO1999001175A1 (de) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2753379B1 (fr) | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
CA2361601A1 (en) * | 1999-02-08 | 2000-08-10 | Cheryl Goldbeck | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
ATE511856T1 (de) | 2000-03-13 | 2011-06-15 | Cornell Res Foundation Inc | Blockieren der leukozytenemigration und entzündung durch störung mit cd99/hec2 |
IL151348A0 (en) | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
AU6475901A (en) | 2000-05-22 | 2001-12-03 | Merck And Company Inc | System and method for assessing the performance of a pharmaceutical agent delivery system |
ATE501161T1 (de) | 2000-12-28 | 2011-03-15 | Wyeth Llc | Rekombinantes schutzprotein aus streptococcus pneumoniae |
WO2002070665A2 (en) | 2001-03-02 | 2002-09-12 | The Rockefeller University | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
US20020198567A1 (en) * | 2001-06-07 | 2002-12-26 | Yona Keisari | Electro-endocytotic therapy as a treatment modality of cancer |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
AU2003230601A1 (en) | 2002-03-07 | 2003-09-22 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Clinical syringe with electrical stimulation aspects |
EP2316922B1 (de) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Humaner neutraliserender Anti-IGFR Antikörper |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
EP1759714A1 (de) * | 2005-09-02 | 2007-03-07 | Bioalliance Pharma | Elektrotransfer von Nukleinsäuren in Gewebezellen |
EP3804809B1 (de) * | 2005-10-03 | 2023-12-27 | Novocure GmbH | Optimierung der eigenschaften eines elektrischen felds zur erhöhung der wirkung des felds auf proliferierende zellen |
JP4961137B2 (ja) * | 2005-12-14 | 2012-06-27 | 久光製薬株式会社 | イオントフォレーシス用デバイス |
WO2008060814A2 (en) | 2006-10-19 | 2008-05-22 | Merck & Co., Inc. | ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF |
PL2068921T3 (pl) | 2006-10-19 | 2014-12-31 | Csl Ltd | Przeciwciała o dużym powinowactwie będące antagonistami receptora alfa1 interleukiny 13 |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US8246176B2 (en) | 2007-03-06 | 2012-08-21 | Sanyo Electric Co., Ltd. | Projection display device having an operation section for displacing a lens |
US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
DK2310500T3 (en) * | 2008-07-18 | 2015-05-11 | Maxcyte Inc | Process for optimizing electroporation |
RU2478396C2 (ru) | 2008-11-05 | 2013-04-10 | ВАЙЕТ ЭлЭлСи | МНОГОКОМПОНЕНТНАЯ ИММУНОГЕННАЯ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЯ, ВЫЗВАННОГО β-ГЕМОЛИТИЧЕСКИМИ СТРЕПТОКОККАМИ (БГС) |
EP3831406B9 (de) | 2010-08-23 | 2024-08-14 | Wyeth LLC | Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen |
MY166172A (en) | 2010-09-10 | 2018-06-07 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
SG11201404730XA (en) | 2012-03-09 | 2014-10-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
EP2964665B1 (de) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogene fusionspolypeptide |
MX380129B (es) | 2013-09-08 | 2025-03-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos |
WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CA3051801A1 (en) | 2017-01-31 | 2018-08-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CN110527625A (zh) * | 2018-05-24 | 2019-12-03 | 苏州壹达生物科技有限公司 | 一种结合高压和低压模式的流式电转染装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9317380D0 (en) * | 1993-08-20 | 1993-10-06 | Therexsys Ltd | Transfection process |
US5641680A (en) * | 1994-11-14 | 1997-06-24 | Zhao; Xi | Gene transfer apparatus and method for using the same |
WO1997007826A1 (en) * | 1995-08-29 | 1997-03-06 | Cbr Laboratories, Inc. | In vivo electroporation of cells |
-
1998
- 1998-06-30 EP EP98938676A patent/EP0993318A1/de not_active Ceased
- 1998-06-30 IL IL13370998A patent/IL133709A0/xx unknown
- 1998-06-30 PL PL98337617A patent/PL337617A1/xx not_active Application Discontinuation
- 1998-06-30 CA CA002295029A patent/CA2295029A1/en not_active Abandoned
- 1998-06-30 CN CN98806793A patent/CN1261812A/zh active Pending
- 1998-06-30 KR KR1019997012430A patent/KR20010014298A/ko not_active Withdrawn
- 1998-06-30 JP JP50807599A patent/JP2002515816A/ja active Pending
- 1998-06-30 WO PCT/EP1998/003976 patent/WO1999001175A1/en not_active Application Discontinuation
- 1998-06-30 AU AU87307/98A patent/AU8730798A/en not_active Abandoned
- 1998-06-30 BR BR9810500-0A patent/BR9810500A/pt not_active IP Right Cessation
-
1999
- 1999-12-29 NO NO996540A patent/NO996540L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9901175A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2295029A1 (en) | 1999-01-14 |
PL337617A1 (en) | 2000-08-28 |
NO996540L (no) | 2000-02-03 |
KR20010014298A (ko) | 2001-02-26 |
IL133709A0 (en) | 2001-04-30 |
AU8730798A (en) | 1999-01-25 |
CN1261812A (zh) | 2000-08-02 |
WO1999001175A1 (en) | 1999-01-14 |
BR9810500A (pt) | 2000-09-05 |
NO996540D0 (no) | 1999-12-29 |
JP2002515816A (ja) | 2002-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0993318A1 (de) | Vorrichtung zur optimierten elektrotransfer der nukleinsäuren vektoren an gewebe in vivo | |
US6939862B2 (en) | Method for transferring nucleic acid into striated muscles | |
JP4664450B2 (ja) | 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ | |
US7054685B2 (en) | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response | |
Vicat et al. | Brief report: muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression | |
EP2428249A1 (de) | Haut- und muskelgerichtete Gentherapie mit hilfe eines gepulsten elektrischen Felds | |
EP1171189B1 (de) | Gerät zur reduzierung durch elektroporationsinduzierte muskelreaktion und schmerzantwort | |
MXPA99011527A (en) | Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo | |
CZ475699A3 (cs) | Systém a zařízení pro in vivo přenos nukleových kyselin do tkání | |
MXPA99011444A (es) | Metodo mejorado de transferencia de acidos nucleicos enmusculo estraido y combinaciones que permienn el uso del procedimiento | |
JP2005524389A (ja) | 宿主組織内への核酸分子の電気的遺伝子導入の増強 | |
AU4439102A (en) | Improved method for transferring nucleic acid into the striped muscle and combination therefor | |
AU4576202A (en) | Improvement in the transfer of nucleic acid into the cells of pluricellular eukaryotic organisms and combination allowing the method to be carried out |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991227 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: SI PAYMENT 19991227 |
|
17Q | First examination report despatched |
Effective date: 20000824 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20021218 |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |